AI Engines For more Details: Perplexity Kagi Labs You
Skin Infections: Fusidic acid is frequently used to treat various types of skin infections, including impetigo, infected dermatitis, infected wounds, and folliculitis. It is effective against a wide range of bacteria commonly found on the skin, including Staphylococcus aureus and Streptococcus species.
Ophthalmic Infections: Fusidic acid may also be formulated as an ophthalmic ointment or eye drops to treat bacterial conjunctivitis (pink eye) and other eye infections caused by susceptible organisms.
Bone and Joint Infections: In some cases, fusidic acid may be used in combination with other antibiotics to treat bone and joint infections, such as osteomyelitis and septic arthritis, particularly when caused by Staphylococcus aureus.
Soft Tissue Infections: Fusidic acid can be effective in treating soft tissue infections, including cellulitis and abscesses, caused by susceptible bacteria.
Nasal Infections: Fusidic acid nasal spray may be prescribed to treat nasal colonization or infection with methicillin-resistant Staphylococcus aureus (MRSA) in certain cases.
Mild to Moderate Infections: Fusidic acid is generally reserved for treating mild to moderate infections and may not be suitable for severe or systemic infections.
Antibiotic Resistance: While fusidic acid is effective against many bacterial strains, resistance to this antibiotic has been reported, particularly in Staphylococcus aureus. Therefore, it is essential to use fusidic acid judiciously and in combination with other antibiotics when necessary to minimize the development of resistance.
Topical Application: Fusidic acid is often applied topically in the form of creams, ointments, or gels directly to the affected area of the skin. It should be used as directed by a healthcare professional, and the affected area should be kept clean and dry.
Adverse Effects: Common side effects of fusidic acid may include local skin reactions such as itching, redness, and irritation at the site of application. Systemic side effects are rare but may include allergic reactions, gastrointestinal disturbances, and headache.
Pregnancy and Lactation: The safety of fusidic acid during pregnancy and breastfeeding has not been well established. It should be used with caution in pregnant or breastfeeding women, and the potential risks and benefits should be discussed with a healthcare provider.
Rank | Probiotic | Impact |
---|---|---|
species | Akkermansia muciniphila | Reduces |
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium bifidum | Increases |
species | Bifidobacterium breve | Increases |
species | Bifidobacterium catenulatum | Increases |
species | Bifidobacterium longum | Reduces |
species | Bifidobacterium pseudocatenulatum | Increases |
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.5 | 0.5 | |
Acne | 0.1 | 0.1 | |
ADHD | 5.8 | 1.6 | 2.62 |
Age-Related Macular Degeneration and Glaucoma | 1 | 0.5 | 1 |
Allergic Rhinitis (Hay Fever) | 3 | 0.8 | 2.75 |
Allergies | 7.1 | 4.2 | 0.69 |
Allergy to milk products | 2.7 | 0.8 | 2.38 |
Alopecia (Hair Loss) | 2.5 | 2.5 | |
Alzheimer's disease | 6.2 | 10.1 | -0.63 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 4.5 | 1.6 | 1.81 |
Ankylosing spondylitis | 5.4 | 3 | 0.8 |
Anorexia Nervosa | 0.5 | 3.5 | -6 |
Antiphospholipid syndrome (APS) | 3.1 | 0.5 | 5.2 |
Asthma | 2.1 | 1.8 | 0.17 |
Atherosclerosis | 1.5 | 3.3 | -1.2 |
Atrial fibrillation | 5 | 2.8 | 0.79 |
Autism | 15.7 | 12.8 | 0.23 |
Barrett esophagus cancer | 1 | 0.5 | 1 |
benign prostatic hyperplasia | 0.3 | 0.3 | |
Bipolar Disorder | 2.3 | 2.5 | -0.09 |
Brain Trauma | 0.5 | 1.6 | -2.2 |
Carcinoma | 5.3 | 3.5 | 0.51 |
Celiac Disease | 4 | 5.7 | -0.43 |
Cerebral Palsy | 1.7 | 2 | -0.18 |
Chronic Fatigue Syndrome | 8.5 | 9.5 | -0.12 |
Chronic Kidney Disease | 3.8 | 3.2 | 0.19 |
Chronic Lyme | 1 | -1 | |
Chronic Obstructive Pulmonary Disease (COPD) | 3.5 | 1.5 | 1.33 |
Chronic Urticaria (Hives) | 2.4 | 2.5 | -0.04 |
Coagulation / Micro clot triggering bacteria | 1.9 | 2 | -0.05 |
Colorectal Cancer | 6.9 | 1 | 5.9 |
Constipation | 2.3 | 1 | 1.3 |
Coronary artery disease | 2.5 | 1.5 | 0.67 |
COVID-19 | 17 | 21.2 | -0.25 |
Crohn's Disease | 12.7 | 8.8 | 0.44 |
cystic fibrosis | 0.9 | 1 | -0.11 |
deep vein thrombosis | 0.9 | 1.5 | -0.67 |
Depression | 14.9 | 13.3 | 0.12 |
Dermatomyositis | 0.6 | 0.6 | |
Eczema | 2.4 | 3 | -0.25 |
Endometriosis | 4.1 | 2.2 | 0.86 |
Eosinophilic Esophagitis | 0.5 | 0.5 | 0 |
Epilepsy | 4.1 | 3.3 | 0.24 |
Fibromyalgia | 4.5 | 4 | 0.13 |
Functional constipation / chronic idiopathic constipation | 7.8 | 6 | 0.3 |
gallstone disease (gsd) | 3.3 | 1 | 2.3 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 3 | 1.5 | 1 |
Generalized anxiety disorder | 2.9 | 1.9 | 0.53 |
giant cell arteritis | 0.5 | -0.5 | |
Glioblastoma | 0.5 | -0.5 | |
Gout | 0.5 | -0.5 | |
Graves' disease | 1.5 | 2 | -0.33 |
Halitosis | 1.5 | 0.5 | 2 |
Hashimoto's thyroiditis | 3.3 | 1 | 2.3 |
Hidradenitis Suppurativa | 1.5 | 0.5 | 2 |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 4.5 | 1.7 | 1.65 |
hypercholesterolemia (High Cholesterol) | 1 | 0.5 | 1 |
hyperglycemia | 0.3 | 2.2 | -6.33 |
Hyperlipidemia (High Blood Fats) | 0.7 | 0.6 | 0.17 |
hypersomnia | 1 | -1 | |
hypertension (High Blood Pressure | 3.8 | 6.6 | -0.74 |
Hypothyroidism | 0.1 | 1.5 | -14 |
Hypoxia | 1.2 | 1.2 | |
IgA nephropathy (IgAN) | 0.1 | 6.5 | -64 |
Inflammatory Bowel Disease | 6.9 | 12.2 | -0.77 |
Insomnia | 1.5 | 1.5 | 0 |
Intelligence | 2 | 1 | 1 |
Intracranial aneurysms | 2 | 0.5 | 3 |
Irritable Bowel Syndrome | 5.9 | 6 | -0.02 |
Liver Cirrhosis | 7.1 | 4.8 | 0.48 |
Long COVID | 13.3 | 13.3 | 0 |
Low bone mineral density | 1.5 | -1.5 | |
Lung Cancer | 1.3 | 2 | -0.54 |
ME/CFS with IBS | 2 | 3.5 | -0.75 |
ME/CFS without IBS | 3.5 | 3 | 0.17 |
Menopause | 2 | 2 | |
Metabolic Syndrome | 13.3 | 13.1 | 0.02 |
Mood Disorders | 20 | 13.8 | 0.45 |
multiple chemical sensitivity [MCS] | 2.2 | 0.5 | 3.4 |
Multiple Sclerosis | 8.1 | 9 | -0.11 |
Multiple system atrophy (MSA) | 3 | 1 | 2 |
Neuropathy (all types) | 1.2 | 0.3 | 3 |
neuropsychiatric disorders (PANDAS, PANS) | 1.1 | 1.1 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4.6 | 6.3 | -0.37 |
NonCeliac Gluten Sensitivity | 0.1 | 0.1 | |
Obesity | 13.3 | 7.2 | 0.85 |
obsessive-compulsive disorder | 10.6 | 6.5 | 0.63 |
Osteoarthritis | 4 | 0.5 | 7 |
Osteoporosis | 2.8 | 1.5 | 0.87 |
pancreatic cancer | 1 | 1 | |
Parkinson's Disease | 4.9 | 7.6 | -0.55 |
Polycystic ovary syndrome | 3.8 | 2.7 | 0.41 |
Postural orthostatic tachycardia syndrome | 0.6 | 0.5 | 0.2 |
Premenstrual dysphoric disorder | 1 | 0.6 | 0.67 |
primary biliary cholangitis | 0.5 | 1.5 | -2 |
Psoriasis | 6.3 | 4.5 | 0.4 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 10.5 | 6.1 | 0.72 |
Rosacea | 1.5 | 1 | 0.5 |
Schizophrenia | 9.9 | 2.5 | 2.96 |
scoliosis | 0.5 | 2 | -3 |
Sjögren syndrome | 4.8 | 4.1 | 0.17 |
Sleep Apnea | 2 | 2.9 | -0.45 |
Small Intestinal Bacterial Overgrowth (SIBO) | 1.6 | 0.4 | 3 |
Stress / posttraumatic stress disorder | 3.9 | 3.5 | 0.11 |
Systemic Lupus Erythematosus | 7.3 | 2.5 | 1.92 |
Tic Disorder | 2 | 2 | 0 |
Tourette syndrome | 0.2 | 0.5 | -1.5 |
Type 1 Diabetes | 6.5 | 3.4 | 0.91 |
Type 2 Diabetes | 13 | 11.9 | 0.09 |
Ulcerative colitis | 4.5 | 8.9 | -0.98 |
Unhealthy Ageing | 10.5 | 2.7 | 2.89 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.